Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Share Price   Awards   Market Scan   Videos   Broker Notes   Director Deals   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Shares Magazine   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Comparison Tables   Spread Betting 
You are NOT currently logged in
 
Register now or login to post to this thread.

Osmetech : The Next Generation - Info and Links thread. (OMH)     

DITCHPIG - 30 Apr 2004 15:09

omhnew4vo.gifomhlogo24kn.gifomhnew4vo.gifomhbot8kj.gif

UBS AG buy 8,825,000 6.7%

eSensor LAUNCHED!!!

FDA clearance for Cystic Fibrosis DNA Test

Sales of the eSensor instrument and CF test will commence in the first half of 2006 as planned.. .

James White, CEO of Osmetech said:

'Gaining FDA clearance for our first microarray based test developed for our new eSensorTM molecular diagnostics instrument is a major step forward for our Molecular Diagnostics Division and will help to establish Osmetech as a key player in the fast growing moleculardiagnostics market. In addition, this FDA clearance helps to validate our microarray technology for routine use in the laboratory.

Critical Care DivisionThe Division has a strong product portfolio and is well placed to continue the growth of instrument placements throughout the world, leading to revenues from proprietary consumables for a number of years to come.Sales of OPTI instruments and consumables remained strong resulting from increased sales of the new touchscreen version of the long-established OPTI (CCA). In 2006 we will start to see an important contribution to sales from the new OPTI LION portable electrolyte analyser and the OPTI R blood gas and electrolyte analyser with reusable consumable as these products are rolled out internationally.'

Molecular Diagnostics DivisionFollowing FDA approval of the eSensorTM platform Osmetech are now looking to progress discussions with strategic partners who are looking for cost effective and easy to use instrumentation and consumables to work on other complex assays both in the healthcare and non healthcare markets. The next Osmetech Molecular test targeted for FDA submission will be the CYP 450 pharmacogenomics assay, which is currently in development.

James White, CEO of Osmetech commented:

'We have been delighted with the rapid integration of the CMS business acquired in July. The powerful combination of the eSensor product together with OPTI GENE provides Osmetech Molecular Diagnostics with an excellent position in this rapidly developing and growing market sector. Both products remain on schedule for launch and revenue generation in the first half of 2006'

Sales to year end up over 40%

Osmetech has reported a strong rise in sales in the latter part of 2005 with growth driven byabove-forecast revenues at its Critical Care blood gas analysis division.. Sales for the Critical Care division in calendar year 2005 exceeded $14.7m, representing an increase of over 60% compared to the calendar year 2004. Approximately half of this overall growth is due to sales to veterinary distribution partner, IDEXX Laboratories, Inc.

Vetstat Exceeds Idexx Expectations

Sales of the VetStat electrolyte and blood gas analyser have been very encouraging and continue to exceed expectations. IDEXX's sales successes and continuing marketing efforts should result in further strong growth for the foreseeable future. As the installed base of instruments becomes established, revenues from proprietary consumables are expected to increase as a proportion of this veterinary business. Following a deal with leading US vetinary hopsital chain Banfield, Idexx are contracted to supply an additional 450 Vetstat devices over the coming year.Good progress is also being made with IDEXX on the development and supply contract to create a new platform for measuring critical care parameters based on Osmetech's proprietary optical fluorescence technology and consumables. It is anticipated that this market leading product is on target for launch late 2006/2007.

Critical Care Product Range - In Production

OPTI-CCA Opti CCA. Sales revenues for this product and consumables were in excess of $14,000,000 in 2005. More than 5000 units are in use worldwide.OPTI-LION Opti Lion. Newly launched in late 2005 this device competes head on with more complex systems. Significant sales are forcast for 2006/7OPTI-R Opti R. Newly launched in late 2005 the OPTI R is a compact blood gas analyzer using a combination of proven maintenance-free sensor technology, intuitive graphic user interface and automated system monitoring to increase operator convenience and reduce time spent on blood gas testing while delivering fast reliable results.OPTI-2L Opti 2 Line. Designed for portability, the Osmetech OPTI Analyzer is always ready for testing wherever you need it for measurement of pH/blood gas, total hemoglobin, oxygen saturation, electrolytes and glucose.

Critical Care Consumable Product Range - In Production

SamplerComfort Sampler. Launched in July 2004 this product, has become the arterial blood sampling method most preferred by therapists and patients. Sales are expected to generate revenues in excess of $2,000,000.Cassette Sensor Cassette. Over 4000 tests per day are made using Opti consumables generating revenues in excess of $8,000,000Callibration The calibration gas bottle assures accurate calibration prior to each sample measurement.DataTrolData Management Software. Consolidate test results in one centralized location

Molecular Diagnostics Product Range - In Production

Opti-GeneOpti-Gene. The system allows for the detection of DNA and RNA targets using PCR or RT-PCR based assays in hospital and clinical research laboratories. Lauching in May first test will be for Factor V Leiden MutationeSensoreSensor. a low cost instrument and consumable for moderately complex genetic testing where the detection of multiple gene targets is required. Initally tests will be for cystic fibrosis and CYP450.BiochipBiochip. Single use bio-chip disposable cartridge for use in the eSensor device.ConsumableConsumables. Disposable cartridge for use in the eSensor device.OPTI Tube OPTI Tube Primary consumable for the OPTI Gene and compatible with the large installed base of LightCycler instrument. Launching from May

Product Range - Licenced to Third Party

VetStat VetStat Based on the OPTI-CCA device. This instrument is being sold in to the vetinary market by industry leading corporation IDEXX. Considerable sales are being made Cassettes Cassette : The only blood gas system calibrated for veterinary-specific reference ranges. An increasing range producing substantial sales. Being sold by Idexx for the Vetstat deviceOPTI Tube OPTI Tube Licensed to Roche to manufacture and sell plastic consumable vials for use on its large installed base of LightCycler instruments. Osmetech plans to manufacture and sell the plastic consumable vials as an alternative to glass vials itself. Sales are anticipated to start early 2006 AVOX 4000 AVOX 4000 The AVOXimeter 4000 provides a fast, accurate assessment of patient oxygenation at the bedside. Sold worldwide (-usa) by Osmetech in a deal with Avox

Buisness Partners
idexxlogo.gifroche_logo.giflogo.gifsysmex_logo.jpg

Major Shareholders
Organisation Shareholding % Gartmore 24,109,657 18.29% Schroder 18,874,284 14.32 UBS AG 8,825,000 6.70TD Waterhouse 7,011,137 5.32 Barclays Nom 6,638,092 5.04 Pershing Keen 5,870,773 4.45HSBC Global Nom 6,544,718 4.97 Roche 2,444,688 1.8 Marlborough UK Micro Cap Director Holdings James White 208,092 Gordon Hall 104,966 D Sandilands 61,597 GB Kuenster 33,054 A Marek 26,190 ADVFN Posters 5,896,564 4.5 Total Holdings 86,648,812 65.7%

Mouse Over Images For Product Data
backup_counter.cgi?counter_id=644347updater.cgi?counter_id=644347&increment=If regular posters would like to be included in the ADVFN figure and if you are not bothered about the figures being public then post your long-term holding here.IE the number of shares you intend to keep for say more than 6 months?Alternatively if you'd rather keep your holdings secret but still want contribute to the overall figure then drop me a line to ditchpig@ntlworld.com

babykitcat - 20 Jan 2005 16:16 - 129 of 242

interesting keep getting this from natwest stockbrokers on line when trying to but OMH shares.
Unfortunately a firm quote is not currently available for your order.

sure the NMS is 50000 i just below this strange never had this before on OMH been trying for nearly 20 mins

babykitcat - 20 Jan 2005 16:30 - 130 of 242

ok cop aload of this you can SELL all you want no problem but u cant buy theses shares at all i just checked!!!

astonvilla - 20 Jan 2005 17:00 - 131 of 242

ummm that looks good then..........

DITCHPIG - 20 Jan 2005 18:55 - 132 of 242

Update with wild rumour...

babykitcat - 20 Jan 2005 19:08 - 133 of 242

oblivously not going to happen but last time i seen this the company announced a take over next day.
wonder if there is something in pipeline for tommo (news on research)really strange as i was trying for ages so it was not just my computer i will try first thing tommo and let u know.
For chartist out there i notice the RSI is at 70


DITCHPIG - 20 Jan 2005 23:45 - 134 of 242

babykitkat,
others are reporting that the quantity available to buy became very limited, however you could sell at 7*nms.

DITCHPIG - 20 Jan 2005 23:50 - 135 of 242

Bangers, are you reading? Can you give Mr Kitkat a chartist view?

babykitcat - 21 Jan 2005 00:13 - 136 of 242

DP what a year we COULD be install 4!!! thanks

babykitcat - 21 Jan 2005 08:02 - 137 of 242

still cant get a firm price!!! DP any ideas

bangersmam - 21 Jan 2005 08:45 - 138 of 242

Kitcat.
Charting these smaller stocks is best kept simple. Oscillators like RSI, Stochastics etc are generaly used in conjuntion with each other to find short term entry / exit points but only work well on more actively traded stocks. Small stocks like OMH can go on being 'overbought' (RSI 70) or 'oversold' RSI 30 for days or weeks therefore giving false signals. Far better to keep it simple and use price, volume, moving averages and MACD.
Hope that helps and its just my opinion.
All the best
big.chart?symb=uk%3Aomh&compidx=aaaaa%3A

DITCHPIG - 21 Jan 2005 09:29 - 139 of 242

so what happens when the pink 200 thingy line turns north Bangers?

babykitcat - 21 Jan 2005 09:35 - 140 of 242

thats it i managed to get a firm quote

DITCHPIG - 21 Jan 2005 11:12 - 141 of 242

L2 for them that wants it.

Bid

2 200,000 3.60 3.75 200,000 2


Time Name NMS Price Price NMS Name Time
Bid
10:29 EVO 100,000 3.60
10:40 WINS 100,000 3.60
07:51 TEAM 100,000 3.50 -
07:53 KBC 100,000 3.40 -
07:35 MLSB 100,000 3.25 -
07:50 KLWT 100,000 3.25 -
07:52 SCAP 100,000 3.25 -

Offer
- 3.75 100,000 MLSB 07:35
- 3.75 100,000 SCAP 07:52
- 3.80 100,000 KBC 07:53
3.90 100,000 EVO 10:29
- 4.00 100,000 KLWT 07:50
- 4.00 100,000 TEAM 07:51
4.00 100,000 WINS 10:40

babykitcat - 21 Jan 2005 11:28 - 142 of 242

not 100% on this L2 but thinks this looks good?

DITCHPIG - 21 Jan 2005 11:33 - 143 of 242

yip!!!

bangersmam - 21 Jan 2005 14:34 - 144 of 242

Looking very strong now, rising on heavy volume. Seems both MM's EVO & WINS are trying to fill orders, pushing the price up in their competition.

babykitcat - 21 Jan 2005 14:40 - 145 of 242

keep it up

babykitcat - 21 Jan 2005 16:23 - 146 of 242

10:29am 900,000 sale (OR WAS IT!!!!)

DITCHPIG - 21 Jan 2005 16:32 - 147 of 242

a 900k sale wouldn't put the price up!

babykitcat - 21 Jan 2005 16:38 - 148 of 242

precisley not right all this market making is it really!!!! all i say is just wait till share starts to go on a roll and we not be making post's like this
Register now or login to post to this thread.